Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 73 full-time employees. The company went IPO on 2004-12-16. The company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. The company is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. The company has established commercial partnerships in Europe and China for certain Phase III assets.
Dr. Silviu Itescu is the Chief Executive Officer of Mesoblast Limited, joining the firm since 2004.
What is the price performance of Mesoblast Limited stock?
The current price of Mesoblast Limited is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Mesoblast Limited?
Mesoblast Limited belongs to Biotechnology industry and the sector is Health Care
What is Mesoblast Limited market cap?
Mesoblast Limited's current market cap is $NaN
Is Mesoblast Limited a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for Mesoblast Limited, including 1 strong buy, 7 buy, 2 hold, 0 sell, and 1 strong sell